Bioeq AG is a Swiss biopharmaceutical joint venture between Polpharma Biologics Group and Formycon and is based in Zug. We license, develop and commercialise a biosimilar, which is a successor product of Lucentis® (ranibizumab), a successful branded biopharmaceutical.

We are a young and dynamic company, supported by an international network of experts. Bioeq AG out-licenses its products to established international pharmaceutical companies who ensure local distribution in each territory.